cas12350-sup-0001-FigS1.docxWord document74KFig. S1. Best percentage change from baseline in target lesions according to dose of buparlisib and radiologic response.
cas12350-sup-0002-FigS2.docxWord document179KFig. S2. Mean buparlisib plasma concentration profile on (A) Cycle 1 Day 1; (B) Cycle 1 Day 8; and (C) Cycle 1 Day 28 (pharmacokinetics analysis set).
cas12350-sup-0003-TableS1.docxWord document20KTable S1. Criteria for dose-limiting toxicities.
cas12350-sup-0004-TableS2.docxWord document19KTable S2. Criteria for grading non-CTCAE adverse events.
cas12350-sup-0005-DataS1.docxWord document17KData S1. Information on pharmacodynamic analyses.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.